Canagliflozin is a recently discovered drug that is used in the treatment of type 2 diabetes, by inhibiting SGLT2 transporters in kidneys that reabsorb glucose from the urine.
EFFICACY:
Cohort studies were made to compare canagliflozin to other molecules (glimepiride and sitagliptin) by evaluating the life quality, weight and HbA1c (glycated hemoglobin) for 52 weeks. it was found that canagliflozin has a better efficacity and a better effective cost ratio.
SIDE EFFECTS:
The most frequent side effects are constipation, thirstiness, nausea, and headache.
Due to its mechanism of action, a high glucosuria can be found also.
Severe complications can occur, like euglycemic ketoacidosis. This drug has a high amputation and risk (like other SGLT2 inhibitors) and a high fracture risk (due to the diminution of the mineralization of the bones).
